Organovo (NASDAQ:ONVO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO) in a research note published on Sunday morning. The brokerage issued a sell rating on the medical research company’s stock.

Organovo Stock Performance

The stock has a fifty day simple moving average of $3.94 and a two-hundred day simple moving average of $4.54. Organovo has a 1 year low of $1.56 and a 1 year high of $21.96. The stock has a market capitalization of $3.47 million, a PE ratio of -2.40 and a beta of 1.13.

Organovo (NASDAQ:ONVO) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($2.28) earnings per share for the quarter, topping the consensus estimate of ($2.52) by $0.24. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.05 million. As a group, equities research analysts forecast that Organovo will post -0.77 earnings per share for the current year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.